Newer blood thinner fails to show advantage in major studies

07/7/2004 | USA Today

Two studies involving nearly 14,000 patients indicate the blood thinner enoxaparin, a newcomer to the market, is no more effective than heparin in treating victims of heart attacks or chest pain. Aventis' enoxaparin is much more expensive than heparin, but is popular with doctors and patients because it can be delivered by injection rather than a continuous IV drip.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN